Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that company management will participate in two upcoming investor conferences in November.
Details of the events are as follows:
Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026, Boston, MA
- Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 10, 2026 at 11:00 a.m. ET
Jefferies Global Healthcare Conference, November 16-19, 2026, London, UK
- Members of management will be available for 1×1 meetings on Thursday, November 19, 2026
The live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261022695225/en/
Media gallery
